Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Dr David Summers who wrote (1058)	6/2/1998 3:47:00 PM
From: Jeffrey L. Henken	Respond to of 2887

August 22, 1996 STRATEGIC ADVISORY, INC. INCREASES 12-18 MONTH TARGET PRICE ON AMERICAN BIOMED, INC. TO $6-8 PER SHARE Strategic Advisory, Inc. announced today it has re-iterated its Strong Buy Recommendation on American BioMed, Inc. (OTC Bul Bd: ABMI), of The Woodlands, TX by increasing its 12-18 month target of $5-6 per share to $6-8 per share. Strategic cites recent positive developments surrounding the Company which should propel its technologically superior products such as the OmniCathr atherectomy catheter to the forefront of cardio-vascular surgical procedures. Strategic stated "Phase II clinical trials for the OmniCathr being conducted at the UCLA Medical Center are underway and according to the principal investigator the first patient had an excellent technical and clinical result and was discharged within 23 hours of this minimally invasive surgical procedure. FDA approval of the device for peripheral use could come as early as June-August 1997. This should result in tremendous top-line growth from this product for American BioMed, Inc." Strategic also cited added valuation due to current negotiations with several major U.S. and international medical companies for purposes advantageous to increasing revenue streams as well as shareholder value. Strategic added, "American BioMed is an extremely attractive takeover candidate in a rapidly consolidating industry and has over $22-million in net operating loss carry-forwards. This is perceived as a very favorable tax consideration to a chief financial officer of any compatible suitor." American BioMed, Inc. develops, manufactures and markets state-of-the-art, medical, surgical and diagnostic devices for minimally invasive medical procedures. American BioMed Minimally Invasive Technology americanbiomed.com Everyone just because an acquisition has not happened to date does not mean it will never happen. Sure it's been almost two years since this was written but obviously American BioMed has been for sale for quite a while to the right bidder. Arterial Vascular Engineering recently bought World Medical for $62 million. Even U S Surgical once a potential suitor of American BioMed has now been acquired. The rate of acquisitions in the healthcare industry is astounding. In the meantime fundamentals continue to improve at American BioMed. Lets concentrate on the future! Regards, Jeff